. 2019 Feb; 13(6):447-452.
doi: 10.1159/000488026.

Adjuvant Dose-Dense Chemotherapy for Breast Cancer: Available Evidence and Recent Updates

Fernando Kude de Almeida 1 Daniela Dornelles Rosa 2 
  • PMID: 30800040
  •     36 References
  •     3 citations


Adjuvant chemotherapy has greatly improved the prognosis of early breast cancer. Dose-dense chemotherapy seeks to increase efficacy by changing the interval between cycles of treatment without the need of increasing doses and toxicity. According to the Gompertzian model, the smaller tumors are and the more rapid they grow, the more benefit could be expected from dose-dense therapy. Some clinical trials showed reduced mortality when adjuvant chemotherapy is administered in shorter intervals, while others had discordant results. Interpreting results is difficult due to a great variability in doses and schemes used in different trials. Dose-dense chemotherapy does not seem to increase adverse events and appears to be the most efficacious in higher-risk individuals and in hormone receptor-negative tumors. This review intends to summarize the available evidence and recent research about this subject.

Keywords: Adjuvant treatment; Anthracyclines; Breast cancer; Chemotherapy; Dose escalation.

Predicting the course of Gompertzian growth.
L Norton, R Simon, H D Brereton, A E Bogden.
Nature, 1976 Dec 09; 264(5586). PMID: 1004590
Highly Cited.
Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma.
C Mayers, T Panzarella, I F Tannock.
Cancer, 2001 Jun 20; 91(12). PMID: 11413512
Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer.
E Baldini, G Gardin, +9 authors, P F Conte.
Ann Oncol, 2003 Feb 04; 14(2). PMID: 12562649
Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study.
P Therasse, L Mauriac, +8 authors, EORTC.
J Clin Oncol, 2003 Mar 01; 21(5). PMID: 12610183
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
I Craig Henderson, Donald A Berry, +16 authors, Larry Norton.
J Clin Oncol, 2003 Mar 15; 21(6). PMID: 12637460
Highly Cited.
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Marc L Citron, Donald A Berry, +18 authors, Larry Norton.
J Clin Oncol, 2003 Apr 02; 21(8). PMID: 12668651
Highly Cited.
Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group.
Gunter von Minckwitz, Günter Raab, +11 authors, Manfred Kaufmann.
J Clin Oncol, 2005 Apr 20; 23(12). PMID: 15837982
Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.
Marco Venturini, Lucia Del Mastro, +11 authors, Paolo Bruzzi.
J Natl Cancer Inst, 2005 Dec 08; 97(23). PMID: 16333028
Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer.
S Kümmel, J Krocker, +5 authors, D Elling.
Br J Cancer, 2006 Apr 20; 94(9). PMID: 16622463    Free PMC article.
The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens.
Richard Simon, Larry Norton.
Nat Clin Pract Oncol, 2006 Aug 09; 3(8). PMID: 16894366
Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313).
Hannah M Linden, Charles M Haskell, +8 authors, Silvana Martino.
J Clin Oncol, 2007 Feb 20; 25(6). PMID: 17308269
Dose-dense therapy in the treatment of early-stage breast cancer: an overview of the data.
Heather L McArthur, Clifford A Hudis.
Clin Breast Cancer, 2008 Feb 20; 8 Suppl 1. PMID: 18282369
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
Chau Dang, Monica Fornier, +17 authors, Clifford Hudis.
J Clin Oncol, 2008 Mar 08; 26(8). PMID: 18323546
Weekly paclitaxel in the adjuvant treatment of breast cancer.
Joseph A Sparano, Molin Wang, +7 authors, Nancy E Davidson.
N Engl J Med, 2008 Apr 19; 358(16). PMID: 18420499    Free PMC article.
Highly Cited.
Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer.
Margot Burnell, Mark N Levine, +11 authors, Lois E Shepherd.
J Clin Oncol, 2009 Nov 11; 28(1). PMID: 19901117    Free PMC article.
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.
Volker Moebus, Christian Jackisch, +14 authors, Michael Untch.
J Clin Oncol, 2010 May 12; 28(17). PMID: 20458045
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.
Chau Dang, Nancy Lin, +10 authors, Clifford Hudis.
J Clin Oncol, 2010 May 19; 28(18). PMID: 20479410    Free PMC article.
Dose-Dense Chemotherapy: Principles, Clinical Results and Future Perspectives.
Marc L Citron.
Breast Care (Basel), 2008 Jan 01; 3(4). PMID: 21076605    Free PMC article.
Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Luisa Bonilla, Irit Ben-Aharon, +3 authors, Salomon M Stemmer.
J Natl Cancer Inst, 2010 Nov 26; 102(24). PMID: 21098761    Free PMC article.
Systematic Review.
Chemotherapy: updates and new perspectives.
Sandra M Swain.
Oncologist, 2010 Dec 16; 15 Suppl 5. PMID: 21138951
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), R Peto, +15 authors, K Pritchard.
Lancet, 2011 Dec 14; 379(9814). PMID: 22152853    Free PMC article.
Highly Cited.
Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.
Helen Gogas, Urania Dafni, +18 authors, George Fountzilas.
Breast Cancer Res Treat, 2011 Dec 22; 132(2). PMID: 22187126
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
Sandra M Swain, Gong Tang, +17 authors, Norman Wolmark.
J Clin Oncol, 2013 Aug 14; 31(26). PMID: 23940225    Free PMC article.
SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.
George T Budd, William E Barlow, +17 authors, Gabriel N Hortobagyi.
J Clin Oncol, 2014 Nov 26; 33(1). PMID: 25422488    Free PMC article.
The development of dose-dense adjuvant chemotherapy.
Clifford Hudis, Chau Dang.
Breast J, 2014 Dec 23; 21(1). PMID: 25530009
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
Lucia Del Mastro, Sabino De Placido, +22 authors, Gruppo Italiano Mammella (GIM) investigators.
Lancet, 2015 Mar 06; 385(9980). PMID: 25740286
Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials.
Fausto Petrelli, Mary Cabiddu, +4 authors, Sandro Barni.
Breast Cancer Res Treat, 2015 Apr 29; 151(2). PMID: 25917869
Systematic Review.
Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.
Joseph A Sparano, Fengmin Zhao, +7 authors, Nancy E Davidson.
J Clin Oncol, 2015 Jun 17; 33(21). PMID: 26077235    Free PMC article.
Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients.
Volker Möbus.
Breast Care (Basel), 2016 Apr 07; 11(1). PMID: 27051389    Free PMC article.
Neoadjuvant Dose-Dense and Dose-Intensified Chemotherapy in Breast Cancer - Review of the Literature.
Mattea Reinisch, Beyhan Ataseven, Sherko Kümmel.
Breast Care (Basel), 2016 Apr 07; 11(1). PMID: 27051390    Free PMC article.
Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
Theodoros Foukakis, Gunter von Minckwitz, +21 authors, Swedish Breast Cancer Group (SweBCG), the German Breast Group (GBG), and the Austrian Breast & Colorectal Cancer Study Group (ABCSG).
JAMA, 2016 Nov 09; 316(18). PMID: 27825007
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
David Cameron, James P Morden, +22 authors, TACT2 Investigators.
Lancet Oncol, 2017 Jun 11; 18(7). PMID: 28600210    Free PMC article.
A Gompertzian model of human breast cancer growth.
L Norton.
Cancer Res, 1988 Dec 15; 48(24 Pt 1). PMID: 3191483
Highly Cited.
Dose: a critical factor in cancer chemotherapy.
E Frei, G P Canellos.
Am J Med, 1980 Oct 01; 69(4). PMID: 6999898
Highly Cited.
Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results.
G Bonadonna, M Zambetti, P Valagussa.
JAMA, 1995 Feb 15; 273(7). PMID: 7837388
Evolving concepts in the systemic drug therapy of breast cancer.
L Norton.
Semin Oncol, 1997 Aug 01; 24(4 Suppl 10). PMID: 9275000
Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer.
Francesca Parisi, Maria Grazia Razeti, +7 authors, Matteo Lambertini.
Clin Med Insights Oncol, 2020 Jul 11; 14. PMID: 32647477    Free PMC article.
Validity of distress thermometer for screening of anxiety and depression in family caregivers of Chinese breast cancer patients receiving postoperative chemotherapy.
Min Yang, Fei Ma, +3 authors, Binghe Xu.
Chin J Cancer Res, 2020 Sep 24; 32(4). PMID: 32963460    Free PMC article.
Synergistic Effect of Doxorubicin and siRNA-Mediated Silencing of Mcl-1 Using Cationic Niosomes against 3D MCF-7 Spheroids.
Supusson Pengnam, Samarwadee Plianwong, +4 authors, Purin Charoensuksai.
Pharmaceutics, 2021 May 01; 13(4). PMID: 33919902    Free PMC article.